Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study

Bilir C., Yildiz I., Bilici A., Ucar M., Berk V., Yildiz Y., ...Daha Fazla

CANCER INVESTIGATION, cilt.35, sa.4, ss.248-255, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1080/07357907.2017.1292518
  • Dergi Adı: CANCER INVESTIGATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.248-255
  • Anahtar Kelimeler: Hemoglobin, predictive, renal cell carcinoma, survival, tyrosine kinase inhibitor, PHASE-III TRIAL, PROGNOSTIC-FACTORS, INTERFERON-ALPHA, BLOOD-PRESSURE, SUNITINIB, SURVIVAL, HYPOTHYROIDISM, INHIBITORS, THERAPY, IMMUNOTHERAPY
  • Gazi Üniversitesi Adresli: Hayır

Özet

Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35months (p < .001) and 21.0 versus 11.36months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions: The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.